Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04959981
Title A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2)
Acronym HERKULES-2
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Erasca, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Duarte California 91010 United States Details
UC Irvine, Chao Family Comprehensive Cancer Center Orange California 92868 United States Details
UC Los Angeles Santa Monica California 90404 United States Details
University of Colorado Aurora Colorado 80045 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Dana Farber Research Institute Boston Massachusetts 02215 United States Details
Henry Ford Health System Detroit Michigan 48202 United States Details
Hackensack University Medical Center (John Theurer Cancer Center) Hackensack New Jersey 07601 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Sarah Cannon Research Institute (Tennessee Oncology) Nashville Tennessee 37203 United States Details
Virginia Cancer Specialists Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field